N La Monica
Overview
Explore the profile of N La Monica including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
1428
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dharmapuri S, Peruzzi D, Marra E, Palombo F, Bett A, Bartz S, et al.
Gene Ther
. 2011 Mar;
18(7):727-33.
PMID: 21390070
Small interfering RNAs (siRNAs) are emerging as promising therapeutic tools. However, the widespread clinical application of such molecules as modulators of gene expression is still dependent on several aspects that...
2.
Dharmapuri S, Aurisicchio L, Neuner P, Verdirame M, Ciliberto G, La Monica N
Cancer Gene Ther
. 2008 Nov;
16(5):462-72.
PMID: 18989354
In vivo electroporation of plasmid DNA (DNA-EP) is an efficient and safe method for vaccines resulting in increased DNA uptake, enhanced protein expression and increased immune responses to the target...
3.
Friso A, Tomanin R, Zanetti A, Mennuni C, Calvaruso F, La Monica N, et al.
Biochim Biophys Acta
. 2008 Aug;
1782(10):574-80.
PMID: 18675343
Mucopolysaccharidosis type II (MPSII) is an inherited disorder due to a deficiency of the lysosomal enzyme iduronate-2-sulfatase (IDS). The disease is characterized by a considerable deposition of heparan- and dermatan-sulfate,...
4.
Elia L, Aurisicchio L, Facciabene A, Giannetti P, Ciliberto G, La Monica N, et al.
Cancer Gene Ther
. 2006 Oct;
14(2):201-10.
PMID: 17053815
Cancer vaccines are a promising approach to treating tumors or preventing tumor relapse through induction of an immune response against tumor-associated antigens (TAA). One major obstacle to successful therapy is...
5.
Salucci V, Mennuni C, Calvaruso F, Cerino R, Neuner P, Ciliberto G, et al.
Scand J Immunol
. 2006 Jan;
63(1):35-41.
PMID: 16398699
T-cell tolerance to tumor antigens is a considerable challenge to cancer immunotherapy. The existence of a murine model transgenic for human carcinoembryonic antigen (CEA) allows CEA vaccination efficacy to be...
6.
Salucci V, Lena A, Ciliberto G, Scarselli E, La Monica N
Scand J Immunol
. 2005 Sep;
62(3):206-17.
PMID: 16179007
Adenovirus vectors encoding carcinoembryonic antigen (Ad-CEA) or costimulatory molecules CD80, intercellular adhesion molecule-1 (ICAM-1) and leucocyte function-associated antigen-3 (LFA-3) (Ad-STIM) were used to transduce murine bone marrow-derived dendritic cells (BMDC)....
7.
Tomanin R, Friso A, Alba S, Piller Puicher E, Mennuni C, La Monica N, et al.
Acta Paediatr Suppl
. 2003 Feb;
91(439):100-4.
PMID: 12572851
Aims: Hunter syndrome is a rare X-linked lysosomal storage disorder caused by the deficiency of the housekeeping enzyme iduronate-2-sulphatase (IDS). Deficiency of IDS causes accumulation of undegraded dermatan and heparan-sulphate...
8.
Aurisicchio L, Bujard H, Hillen W, Cortese R, Ciliberto G, La Monica N, et al.
Gene Ther
. 2002 Feb;
8(24):1817-25.
PMID: 11821934
A major goal in gene therapy is to develop efficient gene transfer protocols that allow tissue-specific, long-term and tightly regulated expression of the desired transgene. This objective is becoming more...
9.
Pieroni L, La Monica N
Curr Opin Mol Ther
. 2001 Nov;
3(5):464-7.
PMID: 11699890
The use of baculovirus vectors for gene expression in mammalian cells is in continuous expansion. These vectors do not replicate in mammalian cells, do not cause a cytopathic effect upon...
10.
Aurisicchio L, Ceccacci A, La Monica N, Palombo F, Traboni C
J Gene Med
. 2001 Sep;
3(4):394-402.
PMID: 11529669
Background: The hepatitis C virus (HCV) is responsible for a severe and widespread form of hepatitis for which a durable and effective therapy has not yet been established. The only...